Zealand Pharma A/S said that the latest clinical data for its prospective type 2 diabetes treatment, lixisenatide (Lyxumia) in combination with long-acting insulin, showed a significant reduction in plasma glucose concentrations (HbA1c). ---Subscribe to MedNous to access this article--- Research & University News Company News
